How Did Andreas Struengmann Make His Money?

Andreas Struengmann’s Profile Summary

Company	Hexal AG
Position	Co-founder
Source of wealth	Pharmaceuticals and biotechnology investments
Also known as	Andreas Strüngmann
Age	76
Education	Medical degree, University at Buffalo
Citizenship	Germany
Residence	Tegernsee, Germany, and South Africa
Family	Married, two children
Website, Social Media	No info

Biography

Andreas Strüngmann, born on February 16, 1950, in Mülheim an der Ruhr, Germany, is a German physician and entrepreneur renowned for his significant contributions to the pharmaceutical and biotechnology industries. He earned his medical degree from the University at Buffalo and initially practiced medicine in Africa. In 1979, Andreas and his identical twin brother, Thomas, joined their father's pharmaceutical company, Durachemie, gaining valuable industry experience.

In 1986, leveraging their industry insights, the Strüngmann brothers co-founded Hexal AG, focusing on generic pharmaceuticals. Under their leadership, Hexal became Germany's second-largest generic drug producer, achieving $1.6 billion in sales during 2004.

In 2005, they sold Hexal and their 67.7% stake in U.S. Eon Labs to Novartis for $7.5 billion, making Sandoz the largest generic-drug company in the world.

Post-Hexal, the brothers established investment firms, including Santo Holding and Athos Service, concentrating on biotech and healthcare sectors. In 2008, they were early investors in BioNTech, providing a €136.5 million seed investment, which played a pivotal role in developing mRNA technology. BioNTech's collaboration with Pfizer led to the successful COVID-19 vaccine, significantly increasing their wealth.

Beyond business, Andreas and his brother founded the Ernst Strüngmann Institute in 2008, a neuroscience research center in Frankfurt named after their father, demonstrating their commitment to scientific advancement.

How did Andreas Struengmann make money?
Andreas Strüngmann built his fortune through strategic investments in the pharmaceutical and biotechnology sectors, primarily through co-founding Hexal AG and his early backing of BioNTech. His business journey began in 1979 when he and his twin brother Thomas took over their father’s pharmaceutical company, Durachemie. After successfully growing the company, they sold it in 1986, providing them with capital to start their next venture.

In 1986, the Strüngmann brothers co-founded Hexal AG, a company focused on producing affordable generic drugs. Hexal grew rapidly and became Germany’s second-largest generic drug manufacturer. The company’s success attracted the attention of Novartis, which acquired Hexal and Eon Labs in 2005 for approximately $7.5 billion. This deal marked a significant turning point in the brothers’ wealth accumulation.

After the sale of Hexal, Andreas and Thomas shifted their focus to biotech and healthcare investments. They established Santo Holding and Athos Service, investment firms that manage their wealth and oversee various ventures. In 2008, they made a pivotal early investment in BioNTech, a biotechnology company specializing in mRNA technology. Their €136.5 million seed investment played a crucial role in BioNTech’s development.

BioNTech’s collaboration with Pfizer to produce a COVID-19 vaccine in 2020 became a game-changer. The vaccine’s success propelled BioNTech to global recognition, significantly increasing the Strüngmann brothers’ wealth. Today, their stake in BioNTech remains one of their most valuable assets, and their fortune is largely tied to their biotech and healthcare investments.

Their ability to identify high-potential investments and support innovation in pharmaceuticals and biotechnology has been the foundation of their financial success.
What is Andreas Struengmann net worth?

As of 2026, Andreas Struengmann’s net worth is estimated to be $14.6 billion.

What is Andreas Struengmann also known as?

Andreas Strüngmann is recognized as a leading German entrepreneur and investor, particularly noted for his contributions to the pharmaceutical and biotechnology industries alongside his twin brother, Thomas.

Prominent achievements

Andreas co-founded Hexal AG, a leading generic drug manufacturer, and was an early investor in BioNTech, contributing to the development of the COVID-19 vaccine. He also established the Ernst Strüngmann Institute for neuroscience research.

What are Andreas Struengmann’s key insights?

Andreas emphasizes innovation and long-term investment in the pharmaceutical and biotechnology sectors, focusing on developing groundbreaking medical solutions.